An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Patients With Generalized Anxiety Disorder.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Escitalopram; Saredutant
- Indications Generalised anxiety disorder
- Focus Registrational; Therapeutic Use
Most Recent Events
- 06 Apr 2011 Biomarkers information updated
- 05 Apr 2011 Last checked against ClinicalTrials.gov record.
- 05 Apr 2011 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.